cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1170Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMПроблема эффективности лечения артериальной гипертонии у курящих пациентовArterial hypertension therapy effectiveness in smokersНебиеридзеД. В.NebieridzeD. V.ПаповаФ. А.PapovaF. A.ИванишинаН. С.IvanishinaN. S.СафарянА. С.SafaryanA. S.ВинницкаяН. Л.VinnitskayaN. L.МелияА.MeliyaA.Государственный научно-исследовательский центр профилактической медицины Росздрава, МоскваState Research Center for Preventive Medicine, State Federal Agency for Health and Social Development, MoscowКардиологическая клиника «Гули», ТбилисиCardiology Clinic «Guly», Tbilisi200720022007618991Copyright © Небиеридзе Д.В., Папова Ф.А., Иванишина Н.С., Сафарян А.С., Винницкая Н.Л., Мелия А., 20072007Небиеридзе Д.В., Папова Ф.А., Иванишина Н.С., Сафарян А.С., Винницкая Н.Л., Мелия А.Nebieridze D.V., Papova F.A., Ivanishina N.S., Safaryan A.S., Vinnitskaya N.L., Meliya A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1170

В обзоре дана краткая характеристика исследований, посвященных изучению эффективности кардиологических препаратов у курящих пациентов. Высказана точка зрения, что различные классы антигипертензивных препаратов по-разному влияют на курящих пациентов с артериальной гипертонией (АГ). Есть мнение, что у курящих больных АГ преимущество имеют препараты, которые улучшают эндотелиальную функцию. Необходима серьезная доказательная база о сравнительной эффективности различных классов антигипертензивных препаратов у курящих.

The review briefly describes the studies on cardiac agents’ effectiveness in smoking patients. Various antihypertensive classes might have different effects in smoking individuals with arterial hypertension (AH). In such patients, medications improving endothelial function might be more effective. At the same time, more evidence is needed to compare various antihypertensive classes’ effectiveness in smokers.

артериальная гипертонияантигипертензивная терапиякурениедисфункция эндотелияarterial hypertensionantihypertensive therapysmokingendothelial dysfunctionReferencesШальнова С.А., Деев А.Д, Р.Г.Оганов. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваск тер профил 2005; 1: 4-9.Шальнова С.А., Деев А.Д, Р.Г.Оганов. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваск тер профил 2005; 1: 4-9.Hughes JR. Four beliefs that may impede progress in the treatment of smoking. Tob Control 1999; 8: 323-6.Hughes JR. Four beliefs that may impede progress in the treatment of smoking. Tob Control 1999; 8: 323-6.Rosenberg L, Kaufman DW, Heirlich SP, et al. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med 1985; 313: 1511- 4.Rosenberg L, Kaufman DW, Heirlich SP, et al. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med 1985; 313: 1511- 4.Heyden S, Schneider KA, Fodor JG. Smoking habits and antihypertensive treatment. Nephron 1987; 47(Suppl 1): 99-103.Heyden S, Schneider KA, Fodor JG. Smoking habits and antihypertensive treatment. Nephron 1987; 47(Suppl 1): 99-103.Barry J, Mead K, Nabel EG. Effect of smoking on the activity of ischemic heart disease. JAMA 1989; 261(3): 398-402.Barry J, Mead K, Nabel EG. Effect of smoking on the activity of ischemic heart disease. JAMA 1989; 261(3): 398-402.Bang LE, Buttenschon L, Kristensen KS, et al. Do we undertreat hypertensive smokers? A comparison between smoking and non-smoking hypertensives. Circulation 1994; 90(1): 248-53.Bang LE, Buttenschon L, Kristensen KS, et al. Do we undertreat hypertensive smokers? A comparison between smoking and non-smoking hypertensives. Circulation 1994; 90(1): 248-53.Journath G, Nilsson PM, Petersson U, et al. Hypertensive smokers have a worse cardiovascular risk profile than non-smokers in spite of treatment-a national study in Sweden. Blood Press 2005; 14(3): 144-50.Journath G, Nilsson PM, Petersson U, et al. Hypertensive smokers have a worse cardiovascular risk profile than non-smokers in spite of treatment-a national study in Sweden. Blood Press 2005; 14(3): 144-50.Марцевич С.Ю., Шальнова С.А.Деев А.Д. и др. Исследование ПРОЛОГ: основные итоги и руководство к действию. Кардиоваск тер профил 2006; 6: 23-6.Марцевич С.Ю., Шальнова С.А.Деев А.Д. и др. Исследование ПРОЛОГ: основные итоги и руководство к действию. Кардиоваск тер профил 2006; 6: 23-6.Fox KM. Smoking, catecholamines and the ischemic myocardium. Postgrad Med 1988; 29(spec. no): 148-51.Fox KM. Smoking, catecholamines and the ischemic myocardium. Postgrad Med 1988; 29(spec. no): 148-51.Лукина Ю.В. Лекарственные препараты и курение. РФК 2005; 1: 31-6.Лукина Ю.В. Лекарственные препараты и курение. РФК 2005; 1: 31-6.Zeiher АM, Schachinger V, Мinnenf. Long-term cigarette smoking impairs endothelium independent coronary arterial vasodilator function. Circulation 1995; 92: 1094-100.Zeiher АM, Schachinger V, Мinnenf. Long-term cigarette smoking impairs endothelium independent coronary arterial vasodilator function. Circulation 1995; 92: 1094-100.Heitzer T, Via Herttuala S, Luoma L, et al. Cigarette smoking potentiates endothelial disfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation 1996; 93: 1346-53.Heitzer T, Via Herttuala S, Luoma L, et al. Cigarette smoking potentiates endothelial disfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation 1996; 93: 1346-53.Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995; 95: 995-1001.Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995; 95: 995-1001.Kumar KV, Das UN. Are free radicals involved in the pathobiology of human essential hypertension? Free Radic Res Commun 1993; 19: 59-66.Kumar KV, Das UN. Are free radicals involved in the pathobiology of human essential hypertension? Free Radic Res Commun 1993; 19: 59-66.Lyons D. Impairment and restoration of nitric oxide – dependent vasodilatation in cardiovascular disease. Int J Cardiol 1997; 62( Suppl 2): S101- 9.Lyons D. Impairment and restoration of nitric oxide – dependent vasodilatation in cardiovascular disease. Int J Cardiol 1997; 62( Suppl 2): S101- 9.Mancini G, Henry G, Mancaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary disease. The TREND (Trial on reversing Endothelial Dysfunction) study. Circulation 1996; 94: 258-65.Mancini G, Henry G, Mancaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary disease. The TREND (Trial on reversing Endothelial Dysfunction) study. Circulation 1996; 94: 258-65.Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative Study of ACE-inhibition, Angiotensin II Antagonism and Calcium Channel Blockade on Flow-mediated Vasodilation in Patients with coronary Disease (BANFF Study). JACC 2000; 35(1): 60-6.Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative Study of ACE-inhibition, Angiotensin II Antagonism and Calcium Channel Blockade on Flow-mediated Vasodilation in Patients with coronary Disease (BANFF Study). JACC 2000; 35(1): 60-6.Lee AF, Dick JB, Bonnar CE, et al. Lisinopril improves arterial function in hyperlipidaemia. Clin Sci (Lond) 1999; 96(5): 441-8.Lee AF, Dick JB, Bonnar CE, et al. Lisinopril improves arterial function in hyperlipidaemia. Clin Sci (Lond) 1999; 96(5): 441-8.Butler R, Morris AD, Struthers AD. Lisinopril improves endothelial function in chronic cigarette smokers. Clin Sci (Lond) 2001; 101(1): 53-8.Butler R, Morris AD, Struthers AD. Lisinopril improves endothelial function in chronic cigarette smokers. Clin Sci (Lond) 2001; 101(1): 53-8.Kotamaki M, Manninen V, Laustiola KA. Enalapril versus atenolol in the treatment of hypertensive smokers. Eur J Сlin Pharmacol 1993; 44(1): 13-7.Kotamaki M, Manninen V, Laustiola KA. Enalapril versus atenolol in the treatment of hypertensive smokers. Eur J Сlin Pharmacol 1993; 44(1): 13-7.Celermajer DS, Sorensen KE, Gooch VM, et al. Non – invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.Celermajer DS, Sorensen KE, Gooch VM, et al. Non – invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.

The authors declare that there are no conflicts of interest present.